¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"fragment length mapping"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • restriction fragment length polymorphism
    Á¦ÇÑÀýÆí±æÀÌ´ÙÇüÅÂ
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • acentric fragment
    ¹«Áß½ÉÀýÁ¶°¢, ¿°»öü´ÜÆí, ¹«Áß½Éü´ÜÆí
  • bone fragment
    »ÄÁ¶°¢, °ñÆí
  • Fc fragment
    FcºÐÀý
  • fallen fragment sign
    ³«ÇÏÆÄÆí¡ÈÄ
  • fracture fragment
    °ñÀýÁ¶°¢, °ñÀýÀýÆí
  • fragment
    Á¶°¢, Æí
  • body surface mapping
    üǥ¸éÀüÀ§Áöµµ
  • brain mapping
    ³úÁöµµÈ­
  • color flow mapping
    »öÇ÷·ùÁöµµÈ­
  • color mapping
    »öÁöµµÈ­
  • chromosome mapping
    ¿°»öüÁöµµÈ­
  • gene mapping
    À¯ÀüÀÚÀ§Ä¡ÁöÁ¤, À¯ÀüÀÚÁöµµÀÛ¼º
  • MR mapping
    ÀÚ±â°ø¸íÁöµµÈ­
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • length
    ±æÀÌ
  • mapping
    ÁöµµÈ­
  • fragment
    Á¶°¢
  • bone fragment
    »ÄÁ¶°¢
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • restriction fragment length polymorphism
    Á¦ÇÑÀýÆí±æÀÌ´ÙÇü¼º
  • acentric fragment
    ¹«Áß½ÉÀýÁ¶°¢, ¿°»öü´ÜÆí, ¹«Áß½Éü´ÜÆí
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • bone fragment
    »ÀÁ¶°¢, °ñÆí
  • fragment
    Á¶°¢
  • fallen fragment sign
    ³«ÇÏÆÄÆí¡ÈÄ
  • fracture fragment
    °ñÀýÁ¶°¢, °ñÀýÀýÆí
  • body surface mapping
    üǥ¸éÀüÀ§µµ
  • brain function mapping
    ³ú±â´ÉÁöµµÈ­
  • color mapping
    »öÁöµµÈ­
  • color flow mapping
    »öÇ÷·ùÁöµµÈ­
  • gene mapping
    À¯ÀüÀÚÀ§Ä¡ÁöÁ¤, À¯ÀüÀÚÁöµµÀÛ¼º
  • mapping
    ÁöµµÈ­
  • MR mapping
    ÀÚ±â°ø¸íÁöµµÈ­
  • spot mapping
    ȯÀڹ߻ýÁöµµÀÛ¼º
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • MR mapping
    ÀÚ±â°ø¸í ÁöµµÈ­
  • F(ab) fragment
    F(ab)Á¶°¢
  • Fab fragment
    Fab ºÐÀý.
  • Fab fragment
    Fab Á¶°¢.
  • Fab fragment
    Fab ºÐÀý
  • Length constant
    ±æÀÌÁö¼ö(¡­ò¦â¦)
  • Length/tension curve
    ±æÀÌ/Àå·Â(íåÕô) °î¼±(ÍØàÊ)
  • acentric fragment
    ¿°»öü´ÜÆí, ¹«Áß½Éü´ÜÆí
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • arm length
    »óÁö Àå(ß¾ò¶íþ), »óÁö ±æÀÌ, ÆÈ ±æÀÌ.
  • fracture fragment
    °ñÀý Æí(Íéï¹ø¸).
  • fragment
    ¼¼Æí, ÆÄÆí(÷òø¸), ´ÜÆí(Ó¨ø¸), ºÐÀý, ÆíÀý, °ñÆí(Íéø¸).
  • fragment
    ÀýÆí, ºÐÀý, Á¶°¢
  • functional profile length
    ±â´ÉÀû(¿äµµ)Ãø¸é?±æÀÌ
  • gap length
    Æ´ÀÇ ±æÀÌ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • restriction fragment length polymorphism
    Á¦ÇѼ¼Æí±æÀÌ´ÙÇü¼º(ð¤ùÚ¼¼Æí¡­Òýû¡à÷)
  • restriction fragment length polymorphism,in cystic fibrosis
    ³¶¼º¼¶À¯Áõ(ÀÇ)¡­(Ò¥àõàéë«ñø¡­)
  • restriction fragment length polymorphism analysis
    Á¦ÇÑÀý´Ü±æÀÌ´ÙÇüÁõºÐ¼®
  • restriction fragment length polymorphism=RFLP
    Á¦ÇÑÀýÆí±æÀ̴پ缺
  • acentric fragment
    ¿°»öü´ÜÆí, ¹«Áß½Éü´ÜÆí
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • body surface mapping
    üǥ¸é(ÀüÀ§)µµ(ô÷øúØüï³êÈÓñ),½ÉÀüµµ Áöµµ(ãýï³Óñò¢Óñ).
  • body surface potential mapping
    üǥ¸é ÀüÀ§µµ(ô÷øúØüï³êÈÓñ).
  • bone fragment
    °ñÆí(Íéø¸), °ñ Á¶°¢.
  • brain function mapping
    ³ú±â´É ÁöµµÈ­
  • cardiac mapping
    ½ÉµµÇØ(ãýÓñú°), ½ÉÀ嵵ǥȭ(ãýíôÓñøúûù)
  • chromosome(s),mapping
    ÁöµµÈ­(ò¢Óñûù)
  • color Doppler flow mapping
    »ö µµÇ÷¯ Ç÷·ù ÁöµµÈ­
  • color doppler flow mapping
    »ö (ßä) µµÇ÷¯ Ç÷·ùÇ¥½Ã (úì×µøúãÆ)
  • color flow mapping
    »ö Ç÷·ù ÁöµµÈ­
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fragment length mapping
    Á¶°¢ ±æÀÌ ÀÛµµ(íÂÓñ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • restriction fragment length polymorphism
    Á¦ÇÑ Á¶°¢±æÀÌ ´ÙÇü¼º(Òýúþàõ)
  • deletion mapping
    °á¼ÕÀÛµµ(ÌÀáßíÂÓñ)
  • denaturation mapping
    º¯¼º ÀÛµµ(ܨàõíÂÓñ)
  • fine-structure genetic mapping
    ¹Ì¼¼ ±¸Á¶(Ú°á¬Ï°ðã) À¯ÀüÀÚ ÀÛµµ(ë¶îîí­íÂÓñ)
  • gene mapping
    À¯ÀüÀÚ ÀÛµµ(ë¶îîí­íÂÓñ)
  • R-loop mapping
    R-·çÇÁ ÀÛµµ(íÂÓñ)
  • S1 mapping
    S1 ÀÛµµ(íÂÓñ)
  • bond length
    °áÇÕ(Ì¿ùê)±æÀÌ
  • chain length
    »ç½½ ±æÀÌ
  • contour length
    ½ÅÀå(ãßíþ)±æÀÌ
  • equivalent chain length
    µî(Ôõ)»ç½½ ±æÀÌ
  • Kuhn statistical length
    Äï Åë°èÀû(÷ÖͪîÜ)±æÀÌ
  • minimal stable length
    ÃÖ¼Ò¾ÈÁ¤(õÌá³äÌïÒ) ±æÀÌ
  • triple-chain length
    »ï(ß²)»ç½½ ±æÀÌ
  • antigen-binding fragment
    Ç׿ø°áÇÕ(ù÷ê«Ì¿ùê) Á¶°¢
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • bone fragment
    °ñÆí
  • fragment
    ¼¼Æí, ÆÄÆí, ´ÜÆí, ºÐÀý, ÆíÀý, °ñÆí
  • gelfoam fragment
    Á©Æû Á¶°¢
  • crown rump length
    µÎÁ¤µÐºÎ±æÀÌ
  • echo train length
    ¿¡ÄÚ¿­±æÀÌ
  • focal length
    ÃÊÁ¡±æÀÌ
  • quarter wave length matching
    4ºÐÇÒÆÄÁ¶È­
  • spatial pulse length
    °ø°£ÆÞ½º±æÀÌ
  • brain function mapping
    ³ú±â´ÉÁöµµÈ­
  • color Doppler flow mapping
    »öµµÇ÷¯Ç÷·ùÁöµµÈ­
  • color flow mapping
    »öÇ÷·ùÁöµµÈ­
  • color mapping
    »öÁ¶ÁöµµÈ­
  • mapping
    Á¦µµ, ÁöµµÈ­
  • MR mapping
    ÀÚ±â°ø¸íÁöµµÈ­
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
FL fatty liver; feline leukemia; femur length; fibers of Luschka; fibroblast-like; filtration leukapher...
EMT emergency medical tag; emergency medical team; emergency medical technician; emergency medical treat...
HGM hog gastric mucosa; human gene mapping; human glucose monitoring
RFLPs Restriction Fragment Length Polymorphisms; Á¦ÇÑÈ¿¼Ò´ÜÆíÀå´ÙÇü
RELP restriction fragment length polymorphism
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AFLP Amplified Fragment Length Polymorphism
FAFLP Fluorescent Amplified Fragment Length Polymorphism
PCR-RFLP PCR restriction fragment length polymorphisms
RFLP PCR)-Restriction fragment length polymorphism
PCR-RFLP Polymerase Chain Reaction-Restriction Fragment Length Polymorphism
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • body surface potential mapping
    üǥ¸é ÀüÀ§µµ
  • brain function mapping
    ³ú ±â´É ÁöµµÈ­
  • chromosome mapping
    ¿°»öü Áöµµ ÀÛ¼º
    ƯÁ¤ÀÇ ¿°»öü »ó¿¡ Àִ ƯÁ¤ÀÇ À¯ÀüÀÚ ºÎÀ§¸¦ °áÁ¤Çϰí, À¯ÀüÀÚÀÇ »ó´ëÀû À§Ä¡¸¦ ³ªÅ¸³»´Â ¿°»öü Áöµµ¸¦ ÀÛ¼ºÇÏ´Â °úÁ¤À» ¸»ÇÑ´Ù. ±â¹ýÀ¸·Î¼­´Â Åë°èÀû ºÐ¼®À» ÀÌ¿ëÇÏ´Â °¡°è ¿¬±¸, ü¼¼Æ÷ ±³Àâ, ¿°»öü °á½Ç ÁöµµÀÇ ÀÛ¼º µîÀ» Æ÷ÇÔÇÑ´Ù.
  • color Doppler flow mapping
    »ö µµÇ÷¯ Ç÷·ù ÁöµµÈ­
  • color mapping
    »öÁ¶ ÁöµµÈ­
  • mapping chromosome
    ÁöµµÈ­ ¿°»öü
    ¼­·Î ¿¬¼âµÇ¾î ÀÖ´Â À¯ÀüÀÚÀÇ °¢°¢ÀÇ À§Ä¡¸¦ ¿°»öü À§ÀÇ »ó´ëÀûÀÎ ¼ø¼­³ª °Å¸®¿¡ µû¶ó¼­ ÇÑ °¡´ÚÀÇ Á÷¼± À§¿¡ µµ½ÄÀûÀ¸·Î ±×·ÁÁø ¿°»öü.
  • amino fragment
    ¾Æ¹Ì³ë ÀýÆí
  • antigen binding fragment
    Ç׿ø °áÇÕ ºÎÀ§
  • bone fragment
    °ñÆí
  • carboxy fragment
    ź¼Ò ÀýÆí
  • detached fragment
    À¯¸®Æí, À¯¸® °ñÆí
  • enkephalin fragment
    ¿£ÄÉÆÈ¸° ºÐÀý
  • fracture fragment
    °ñÀý Æí
  • fragment
    ºÐÀý, ¼¼Æí, ÆÄÆí, ´ÜÆí, ÆíÀý, °ñÆí
    Å« Àüü°¡ ÆÄ±«µÇ¾î Çü¼ºµÈ ¼ÒÆí.
  • multiple biologically active peptide fragment
    ´Ù¹ß¼º »ý¹°ÇÐÀû Ȱ¼º ÆéŸÀÌµå ºÐÀý
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
amplified fragment length polymorphism <technique> Invented by KeyGene, a Dutch biotech company based in Wageningen, Holland. The technique is now merchandised under licence agreement by Perkin Elmer.
Selected markers are amplified in a PCR, which makes amplified fragment length polymorphism an easy and fast tool for strain identification in agriculture, botany, microbiology and animal breeding.
Acronym: AFLP
(05 Feb 1998)
restriction fragment length polymorphism <molecular biology, technique> A method that allows familial relationships to be established by comparing the characteristic polymorphic patterns that are obtained when certain regions of genomic DNA are amplified (typically by PCR) and cut with certain restriction enzymes.
The variation in the length of DNA fragments produced by a restriction endonuclease that cuts at a polymorphic locus. Such variations are generated by mutations that create or abolish recognition sites for these enzymes.
This is a key tool in DNA fingerprinting, reflecting the existence of different alleles in the individual. Restriction fragment length polymorphism mapping is also used in plant breeding to see if a key trait such as disease resistance is inherited.
In principle, an individual can be identified unambiquously by restriction fragment length polymorphism hence the use of restriction fragment length polymorphism in forensic analysis of blood, hair or semen).
Similarly, if a polymorphism can be identified close to the locus of a genetic defect, it provides a valuable marker for tracing the inheritance of the defect.
Synonym: DNA fingerprinting.
Acronym: RFLP
(12 Jan 1998)
acentric fragment A fragment of a chromosome lacking a centromere and unable to attach to the mitotic spindle, therefore unable to take part in the division of a nucleus and randomly distributed in daughter cells.
Synonym: acentric fragment.
(05 Mar 2000)
body surface potential mapping Recording of regional electrophysiological information by analysis of surface potentials to give a complete picture of the effects of the currents from the heart on the body surface. It has been applied to the diagnosis of old inferior myocardial infarction, localization of the bypass pathway in wolff-parkinson-white syndrome, recognition of ventricular hypertrophy, estimation of the size of a myocardial infarct, and the effects of different interventions designed to reduce infarct size. The limiting factor at present is the complexity of the recording and analysis, which requires 100 or more electrodes, sophisticated instrumentation, and dedicated personnel.
(12 Dec 1998)
Brimacombe fragment A ribonucleoprotein fragment obtained by mild ribonuclease treatment of ribosomes.
(05 Mar 2000)
butterfly fragment A broad triangular fragment that is commonly present in comminuted fractures of the diaphysis.
(05 Mar 2000)
cardiac mapping A method by which local cardiac potentials are spatially depicted in an integrated manner as a function of time (isochrone map) or potential (isopotential map).
(05 Mar 2000)
gene mapping Determination of the relative positions of genes on a DNA molecule (chromosome or plasmid) and of the distance, in linkage units or physical units, between them.
(09 Oct 1997)
mapping See: gene mapping, linkage map, physical map.
(09 Oct 1997)
mapping function In linkage analysis, a formula that converts the recombination fraction (which is on the probability scale) into map distance (in morgans).
(05 Mar 2000)
mapping, gene Charting the positions of genes on chromosome and learning the distance, in linkage units or physical units, between genes.
(12 Dec 1998)
genetic mapping Determination of the relative positions of genes on a DNA molecule (chromosome or plasmid) and of the distance, in linkage units or physical units, between them.
(14 Nov 1997)
restriction fragment <molecular biology> The fragments of DNA generated by digesting DNA with a specific restriction endonuclease. Each of the fragments ends in a site recognised by that specific enzyme.
(10 Mar 1998)
restriction mapping Use of restriction endonucleases to analyze and generate a physical map of genomes or genes. The nucleotide sequence determined is often then translated into an amino acid sequence, providing a means for sequencing the protein for which the gene codes, or for which the mRNA is a messenger.
(12 Dec 1998)
peptide mapping Two-dimensional separation and analysis of peptides.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fission fragment
    Çٺп­ÀÇ ÆÄÆí
  • fragment
    ÆÄÆí;´ÜÆí;¹Ì¿Ï¼º À¯°í;ºÎ¼­Áø Á¶°¢;»ê»êÀÌ ºÎ¼ö´Ù;»ê»ê Á¶°¢ÀÌ µÇ´Ù;ºÎ¼­Áö´Ù
  • gene mapping
    À¯ÀüÀÚ Áöµµ(¿°»öü»óÀÇ À¯ÀüÀÚ ÀÚ¸®¸¦ °áÁ¤Çϱâ)
  • mapping
    Áöµµ Á¦ÀÛ;»ç»ó;ÇÔ¼ö 
  • at length
    µåµð¾î, »ó¼¼È÷, ÃæºÐÈ÷
  • length
    ±æÀÌ
  • cable('s) length
    ¿¬(100-120±æ(fathoms);¾à 185m)
  • field length
    ÀÌÂø·ú ȰÁÖ °Å¸®
  • focal length
    ÃÊÁ¡°Å¸®
  • graduated length method
    Á¡Â÷Àû ±æÀÌ º¯°æ¹ý(±â¼úÀÇ Çâ»ó¿¡ µû¶ó ½ºÅ°¸¦ ±ä °ÍÀ¸·Î Á¡Â÷ ¹Ù²Ù¾î °¡´Â ½ºÅ° Áöµµ¹ý)
  • length
    ±æÀÌ;±âÀå;¼¼·Î;±â°£;1¸¶½Å;at full ~ ±æ°Ô;at ~ µåµð¾î;go all ~s;or go to grent(any)~ ¾î¶² ÀÏÀÌ¶óµµ ÇØÄ¡¿ì´Ù
  • whole-length
    ÀüÀå(Àü½Å)ÀÇ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á